USPTO serial 87588377
LYMPHOQUANT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 1, 2021
- Examiner
- CLARK, ROBERT C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with LYMPHOQUANT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
SAN DIEGO, CA, US
SAN DIEGO, CA, US
Invivoscribe Technologies, Inc.
San Diego, CA, US
Invivoscribe Technologies, Inc.
San Diego, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sarah W. Matthews
Sarah W. Matthews Dentons Durham Jones Pinegar3301 N Thanksgiving Way, Suite 400Lehi, UT 84043United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Reagents for scientific and research use, namely, buffer solutions, enzymes, molecular probes, DNA and RNA polymerases, nucleic acids, nucleic acid derivatives, primers for use in PCR, DNA templates, RNA templates, dyes and biotechnology reagents and solvents for sample preparation, purification, lysis, modification and manipulation of cells; diagnostic reagent kits for scientific and research use comprised of buffer solutions, enzymes, molecular probes, DNA and RNA polymerases, nucleic acids, nucleic acid derivatives, primers for use in PCR, DNA templates, RNA templates, dyes and biotechnology reagents and solvents for sample preparation, purification, lysis, modification and manipulation of cells; diagnostic reagent kits for scientific and research use comprised of chemical and biological reagents for non-medical purposes; diagnostic reagents for scientific and research use; diagnostic assays for research, clinical research, and laboratory research use | ACTIVE | Sep 8, 2019 |
| 005 | Assays for the treatment or diagnosis of disease; medical diagnostic reagents, namely, buffer solutions, enzymes, molecular probes, DNA and RNA polymerases, nucleic acids, nucleic acid derivatives, primers for use in PCR, DNA templates, RNA templates, dyes and biotechnology reagents and solvents for sample preparation, purification, lysis, modification and manipulation of cells; medical diagnostic kits comprised of buffer solutions, enzymes, molecular probes, DNA and RNA polymerases, nucleic acids, nucleic acid derivatives, primers for use in PCR, DNA templates, RNA templates, dyes and biotechnology reagents and solvents for sample preparation, purification, lysis, modification and manipulation of cells; medical diagnostic reagent kits comprised of chemical and biological reagents for the treatment, monitoring and diagnosis of disease; medical diagnostic reagent kits comprised of medical reagents for clinical or medical use; medical diagnostic assays for the treatment and diagnosis of disease; medical diagnostic assays for testing of bodily fluids | ACTIVE | Sep 8, 2019 |
| 042 | DNA analysis services for scientific research purposes, namely, DNA sequencing, bioinformatics analysis, and interpretation of biological DNA data generated from reagents and assays | ACTIVE | Oct 31, 2017 |
| 044 | DNA screening for medical purposes, namely, DNA sequencing, bioinformatics analysis, and interpretation of biological DNA data generated from reagents and assays | ACTIVE | Oct 31, 2017 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by INVIVOSCRIBE, INC.
- Other trademarks owned by INVIVOSCRIBE, INC.
- Other trademarks owned by Invivoscribe Technologies, Inc.
- Other trademarks owned by Invivoscribe Technologies, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named LYMPHOQUANT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 1, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Oct 10, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 10, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 10, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 1, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 28, 2021 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Apr 27, 2021 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Apr 26, 2021 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Apr 26, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Mar 25, 2021 | IUAF | USE AMENDMENT FILED | — |
| Mar 25, 2021 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Oct 2, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 1, 2020 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Sep 30, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Sep 24, 2020 | EXT5 | SOU EXTENSION 5 FILED | — |
| Sep 24, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 27, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 25, 2020 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Mar 25, 2020 | EXT4 | SOU EXTENSION 4 FILED | — |
| Mar 25, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 28, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 26, 2019 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Sep 26, 2019 | EXT3 | SOU EXTENSION 3 FILED | — |
| Sep 26, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 23, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 21, 2019 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 21, 2019 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 21, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 29, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 27, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Sep 27, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| Sep 27, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 5, 2018 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Mar 28, 2018 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 28, 2018 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 27, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 30, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 30, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 10, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 26, 2017 | ALIE | ASSIGNED TO LIE | — |
| Dec 5, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 5, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 5, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 5, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 5, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 4, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 6, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 1, 2017 | NWAP | NEW APPLICATION ENTERED | — |